
Novo Nordisk makes Eddie Williams senior VP
pharmafile | February 3, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Novo Nordisk, eddie williamsÂ
Novo Nordisk has promoted Eddie Williams to the position of senior vice president of its biopharmaceuticals unit.
Williams brings three decades of experience in the pharma industry to the firm. He joined Novo Nordisk in 2006 and previously served as the corporate vice president of biopharmaceuticals.
In this capacity, he leads the sales and marketing, business development and new product commercialisation functions for the company’s US biopharma business.
Jesper Hoiland, president of the Denmark-based firm said: “Our biopharmaceutical business will be increasingly important to our growth in the US as we apply the protein expertise developed through our diabetes franchise to helping people with haemophilia and growth disorders manage their conditions more effectively.”
“That business has flourished under Eddie’s experienced leadership. His promotion to senior vice president demonstrates the company’s focus on, and commitment to, our pipeline of life-changing biological therapies.”
Related Content

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …






